Medtronic's Inceptiv Closed-Loop SCS Shows Strong 12-Month Pain Relief Data

Medtronic's latest clinical trial data reveals compelling evidence for the effectiveness of its Inceptiv closed-loop spinal cord stimulator (CL-SCS) in treating chronic low-back and leg pain. The 12-month results, scheduled for presentation at the upcoming North American Neuromodulation Society (NANS) 2025 meeting in Orlando, showcase significant improvements in pain management and quality of life metrics.

The Inceptiv system, which received FDA approval in April 2024, represents a significant advancement in neuromodulation technology. As the world's smallest and thinnest fully implantable SCS device, it features innovative closed-loop technology that continuously adapts stimulation based on individual patient signals.

Clinical Efficacy and Patient Outcomes

The trial demonstrated remarkable pain relief outcomes, with 82% of participants reporting at least a 50% reduction in low-back pain intensity, achieving a mean reduction of 67%. Notably, half of the study participants were able to reduce or discontinue their opioid medications, marking a significant advancement in pain management alternatives.

Dr. Vahid Mohabbati, director of the Sydney Pain Research Centre and trial investigator, emphasized the significance of these findings: "The 12-month data demonstrate that Inceptiv with closed-loop technology provides significant benefits in improving pain, quality of life and physical function scores while substantially reducing overstimulation."

Advanced Technology Performance

The study revealed impressive technical performance metrics, with 93% of patients reporting reduced overstimulation during in-clinic testing when using the closed-loop feature. The technology's effectiveness extended to real-world applications, with 91% of participants reporting no uncomfortable stimulation during daily activities.

A particularly noteworthy finding was the minimal need for manual adjustments - patients made only one median adjustment to programming every 30 days with the closed-loop feature activated. This represents a significant improvement over current market standards, where 50% of SCS users typically require adjustments several times per week.

Patient Satisfaction and Quality of Life

Patient satisfaction rates were exceptional, with 100% of participants expressing satisfaction with the CL-SCS therapy and 98% indicating they would recommend it to friends and family. The study demonstrated that 88% of patients preferred having the closed-loop feature activated rather than deactivated.

Dr. Ashwini Sharan, chief medical officer of Medtronic's Neuromodulation business, noted: "These results add to the growing body of high-quality evidence demonstrating the long-term efficacy of SCS in reducing pain and improving quality of life. The reduced need for manual adjustments, combined with positive therapy experience and satisfaction, may lead to better therapy compliance and durability of outcomes."

Study Design and Future Outlook

The trial successfully met both its primary endpoint of reducing overstimulation and secondary endpoints related to pain reduction. The research team plans to continue monitoring outcomes through 18- and 24-month follow-up periods, which will provide additional insights into the long-term effectiveness of the therapy.

The positive results from this study suggest that Inceptiv's closed-loop technology could represent a significant advancement in chronic pain management, offering patients a more automated and personalized approach to spinal cord stimulation therapy.